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Abstract: Vaginal formulations for the prevention of sexually transmitted infections are 
currently gaining importance in drug development. Polysaccharides, such as chitosan and 
carrageenan, which have good binding capacity with mucosal tissues, are now included in 
vaginal delivery systems. Marine polymer-based vaginal mucoadhesive solid formulations 
have been developed for the controlled release of acyclovir, which may prevent the sexual 
transmission of the herpes simplex virus. Drug release studies were carried out in  
two media: simulated vaginal fluid and simulated vaginal fluid/simulated seminal fluid 
mixture. The bioadhesive capacity and permanence time of the bioadhesion, the prepared 
compacts, and compacted granules were determined ex vivo using bovine vaginal mucosa 
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as substrate. Swelling processes were quantified to confirm the release data. 
Biocompatibility was evaluated through in vitro cellular toxicity assays, and the results 
showed that acyclovir and the rest of the materials had no cytotoxicity at the maximum 
concentration tested. The mixture of hydroxyl-propyl-methyl-cellulose with chitosan- or 
kappa-carrageenan-originated mucoadhesive systems that presented a complete and 
sustained release of acyclovir for a period of 8–9 days in both media. Swelling data 
revealed the formation of optimal mixed chitosan/hydroxyl-propyl-methyl-cellulose gels 
which could be appropriated for the prevention of sexual transmission of HSV. 
Keywords: chitosan; kappa-carrageenan; vaginal mucoadhesive formulations; acyclovir 
controlled release; swelling behaviour; cytotoxicity; genital herpes; ex vivo bioadhesion 
 
1. Introduction 
Sexually transmitted infections (STIs) are a major global cause of acute illness, infertility, long-term 
disability, and death, with severe medical and psychological consequences for millions of men, women 
and infants. 
WHO/Europe advocates and assists Member States in promoting and developing human-rights-based 
policies and practices for STI control and prevention. According to the World Health Organization, 
sexually transmitted diseases (STDs) and their complications are among the top five diseases in 
developing countries forcing patients to seek healthcare [1]. Neonatal diseases acquired by vertical 
transmission are serious complications associated with significant morbidity and mortality. STDs are 
also the second cause of disease-related death and loss of years of good health among young women of 
child-bearing age (excluding HIV). 
Genital herpes is one of the most common sexually transmitted infections worldwide, with a global 
prevalence of 536 million people infected and an annual incidence of 23.6 million new cases [2,3]. 
This chronic disease is caused by the Herpes simplex virus (HSV) type 2, and presents a wide 
variability in its clinical manifestations, ranging from asymptomatic to mild or severe signs and 
symptoms with potential complications. There are consequently many non-diagnosed cases of genital 
HSV, as many people infected with HSV are unaware of their infection [4]. Over the last thirty years, 
epidemiologic and molecular studies have highlighted a strong and synergistic relationship between 
HSV-2 and the Human Immunodeficiency Virus-1 (HIV-1), which clearly points to their capacity for 
co-infection [5]. It should be noted that HSV-2 infection, even without recognized lesions, is  
an independent risk factor for HIV infection, such that the risk of HIV acquisition is three times higher 
in people with HSV-2. The resulting mucosal disruption caused by genital ulcers offers an effective 
entry route for HIV-1. This could be prevented by high concentrations of antiviral in the genital mucosa, 
thereby reducing the increased susceptibility to HIV-1 infection associated with HSV-2 [6–9].  
While the probability of male-to-female transmission of STDs is alarmingly high, the same is not 
universally true for female-to-male transmission. Current methods of preventing STDs, such as 
abstinence, condoms, and monogamy are frequently ineffective and out of women’s control [10], 
making it advisable to design novel female-controlled barrier techniques, such as microbicides and 
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female condoms [11]. Microbicides are currently emerging as a promising tool to protect women from 
STDs. A vaginal microbicide is any topical agent/formulation intended to prevent sexual pathogens, 
either by inactivating or killing cellular mechanisms, by forming a physical barrier between cells and 
pathogens, or by enhancing the natural protective mechanisms of the cervix and vagina. Unfortunately, 
many vaginal microbicide formulations may fail to elicit a protective response due to their lack of 
efficacy and inadequate formulation. Some of the most commonly used vaginal dosage forms include 
creams, gels, tablets, films, tampons, vaginal rings, and douches. Each of these formulations has 
specific advantages and limitations. Tablets can also be designed to perform a controlled-release of the 
microbicide over a prolonged period of time. 
Several studies reveal that acyclovir (ACV) is a safe and effective drug for vaginal administration, 
and some clinical benefits have been observed in the treatment of primary or recurrent lesions from 
genital herpes [12,13]. Several studies on the prevention of genital herpes transmission have examined 
the inclusion of acyclovir as a microbicide drug in vaginal formulations such as gels [14], intravaginal 
rings [15,16], microporous matrices [17] or nanoparticles [18]. Vaginal bioadhesive tablets of acyclovir 
have been developed using different excipients such as methyl-cellulose, carboxy-methyl-cellulose, 
hydroxyl-propyl-cellulose, showing the dissolution results an inadequate behavior because of 
disintegration of tablets in the first 30 min. However, when hydroxyl-propyl-methyl-cellulose was 
incorporated to tablets, ACV release was prolonged during at least 8 h [19]. Gurumurthy et al. 
designed xanthan gum/Carbopol® 934P-based acyclovir vaginal tablets obtaining sustained drug 
release data for 12 h in simulated vaginal fluid [20]. 
Mucoadhesive polymers have an excellent binding capacity with mucosal tissues over  
a considerable period of time. Several studies have been conducted on the incorporation of tragacanth, 
Carbopol®, Poloxamer 407®, pectin, sodium alginate, cellulose derivatives, and chitosan, among 
others, into vaginal formulations in order to increase the residence time of these formulations at the site 
of action [21–23]. 
Chitosan is a natural polysaccharide produced by the partial deacetylation of chitin, the structural 
element in the exoskeleton of crustaceans such as crabs and shrimps. The amino group in chitosan has 
a pKa value of approximately 6.5, which leads to protonation in an acidic solution with a density of 
charge dependent on the pH and the % deacetylation value. Chitosan has water soluble and 
bioadhesive properties with negatively charged surfaces, such as mucosal membranes, and can be used 
to transport a drug to an acidic environment where it can be degraded, thereby releasing the drug to the 
desired site. It is biocompatible and biodegradable and is widely used as a pharmaceutical excipient in 
a range of formulations such as powders, tablets, emulsions, and gels. The use of chitosan as a 
mucoadhesive polymer for vaginal delivery systems has been studied by several researchers [24–26]. 
Carrageenan is a member of the family of linear sulfated polysaccharides extracted from red edible 
seaweeds, which are widely used in the pharmaceutical industry for their gelling, thickening, and 
stabilizing properties. There are three main varieties of carrageenan, with differing degrees of 
sulfation. Kappa-carrageenan has one sulfate group per disaccharide, iota-carrageenan has  
two sulfates per disaccharide and lambda carrageenan has three. Liu et al. [27] developed an in situ 
kappa-carrageenan/poloxamer 407 vaginal gel with prolonged local residence. There is also evidence 
that carrageenan-based gel may offer some protection against HSV-2 transmission by binding with the 
receptors on the herpes virus, thus preventing the virus from binding to cells [28]. 
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Cellulose derivatives have also been applied as drug delivery excipients in vaginal formulations. 
For instance, hydroxyl-ethyl-cellulose is a FDA-approved polymer found in a wide range of 
applications, because it is non-irritant and non-toxic to the vagina [29,30]. Methylcellulose has been 
used in the development of vaginal hydrogels due to its good biocompatibility and bioadhesion [31]. 
Other formulations, such as vaginal rings, gels or creams, vaginal tablets and compacts are easily 
manufactured, economical, stable under different environmental conditions, and easy to handle. If 
these solid formulations include the appropriate mucoadhesive polymer, or polymer mixture, an 
optimum formulation can be obtained for the in situ controlled release of the drug in the area where the 
transmission of vaginal herpes occurs. 
With this background, the aim of this paper is to develop natural polymer-based vaginal mucoadhesive 
solid formulations for the controlled release of acyclovir, which may prevent the sexual transmission 
of HSV. Infection with HSV can increase the risk of infection with other pathogens, such as HIV. 
2. Results and Discussion 
In order to achieve optimal acyclovir controlled release mucoadhesive formulations, two types of 
solid systems were prepared containing 100 mg of acyclovir and natural and/or semisynthetic 
mucoadhesive polymers: compacts and compacted granules. Table 1 shows the composition (mg/unit) 
of these formulations. 
Table 1. Composition (mg/unit) of prepared compacts and compacted granules. 
Batch Chitosan k-Carrageenan HPMC100 ACP PVP MgS Acyclovir
CQ 225     3 100 
CK  225    3 100 
CH   225   3 100 
CQH1 135  90   3 100 
CQH2 90  135   3 100 
CKH1  135 90   3 100 
CKH2  90 135   3 100 
CGQH1 135  90 45 27 3 100 
CGQH2 90  135 45 27 3 100 
CGKH1  135 90 45 27 3 100 
CGKH2  90 135 45 27 3 100 
2.1. Release Studies 
Figure 1 shows the release profiles of acyclovir for all formulations assayed in simulated vaginal 
fluid (SVF) (graphs A, B, and C) and simulated vaginal fluid/simulated seminal fluid mixture 
(SVF/SSF) (graph D). The data from compacts prepared with polymer/acyclovir binary physical mixtures 
(CQ, CK, and CH) show that all the polymers control acyclovir release, but at different rates  
(graph A). 
Kappa-carrageenan compacts (CK) produced drug release in 48 h, while samples of chitosan 
formulation (CQ) extend ACV release to 120 h. In both cases the swelling, disintegration, and 
dissolution of the formulation—the mechanisms controlling the release of A—were visually observed. 
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Drug release was more prolonged when ACV was formulated with HPMC (CH), and the release was 
incomplete, as an asymptotic trend was observed in the release profile after 92 h of the test. At the 
conclusion of the release study it was observed that the CH compact core remained dry.  
The explanation is that in an aqueous medium HPMC forms a strong gel layer that prevents fluid from 
accessing the compact and hinders the dissolution of 100% of the dose of acyclovir. In the light of 
these findings, new formulations were designed combining a marine origin polymer such as chitosan 
or kappa-carrageenan with HPMC in order to exploit the benefits of both types of polymers.  
These include the swelling/dissolution—shown by the natural polymers studied—and the robustness of 
HPMC, which swells but will not dissolve in an aqueous medium. Figure 1 (graph B) shows the ACV 
release profiles obtained from the compacts formulated with the marine polymer/HPMC mixtures.  
As can be noted from the data, chitosan/HPMC compacts (CQH1 and CQH2) allow a complete and 
sustained release of ACV over a period of 168 h. Moreover, there are no appreciable differences 
between both profiles although they contain different chitosan/HPMC ratios. In contrast,  
kappa-carrageenan/HPMC compacts show total ACV release, but the time needed to achieve this 
depended on the kappa-carrageenan/HPMC ratio. The formulation containing the highest ratio of 
kappa-carrageenan (CKH1) released 100% of ACV in 120 h, whereas the CKH2 formulation required 
192 h to release all of the drug. This may be the result of the ability of the kappa-carrageenan compacts 
to erode, as has been described by Bettini et al. [32] for the metoprolol/λ-carrageenan matrix.  
The chitosan-based compacts showed a strong interaction between chitosan and HPMC, and a more 
controlled release of ACV, regardless of the chitosan/HPMC ratio. 
 
Figure 1. Acyclovir release profiles obtained from compacts and compacted granules in 
simulated vaginal fluid (A, B, and C) and simulated vaginal fluid/simulated seminal fluid 
mixture (D). All values represent the mean ± SD (n = 3). 
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In order to prolong ACV release time, compacted granules were made by granulating physical 
ACV/polymer mixtures. Figure 1C shows the dissolution profiles of ACV for the compacted granule 
formulations. In all cases total drug release was obtained in a period of nine days (216 h). Although the 
systems containing the chitosan/HPMC mixture showed better controlled release of ACV, the 
granulation process can generally be assumed to lead to unitary systems (granules) where the presence 
of a binder (PVP K30) ensures the ACV+HPMC+marine polymer physical bond. The subsequent 
granule compaction produced robust formulations which enabled the sustained release of ACV.  
Since these formulations present superior ACV controlled-release characteristics, they were also tested 
in the simulated vaginal fluid/simulated seminal fluid mixture (SVF/SSF) to assess how the nature of 
the medium affected the ACV release process. The results of ACV released from CGQH1, CGQH2, 
CGKH1, and CGKH2 in the SVF/SSF mixture are shown in Figure 2D, and indicate that formulations 
with chitosan (CGQH1 and CGQH2) had a higher ACV controlled release. This is because  
pH-dependent chitosan dissolves better in an acidic medium (SVF) than in a neutral medium 
(SVF/SSF). Based on the results of the release studies, it can be concluded that chitosan-based systems 
may be the most suitable for use in preventing the sexual transmission of genital herpes.  
Although controlled ACV release was one of the aims of this research, it is also essential to verify 
whether the formulation has mucoadhesive properties. We, therefore, determined the bioadhesion of all 
the systems developed. 
2.2. Characterization of Bioadhesion 
The bioadhesive behavior of the compacts and compacted granules containing chitosan and  
kappa-carrageenan and HPMC are shown in Figure 2. All formulations show higher values for bioadhesion 
work and maximum detachment force in vaginal mucosa than for chitosan- and HPMC-based 
mucoadhesive acyclovir tablets in gastric mucosa [33], and for different mucoadhesive semisolid 
formulations (gel-type, such as Crinone, KYJelly, zidoval, and W/S mucoadhesive emulsions) [34]. 
The bioadhesive behavior of the compacts and compacted granules containing chitosan,  
kappa-carrageenan and/or HPMC are shown in Figure 2A. As expected, all the formulations had 
mucoadhesive ability. 
The data on maximum detachment (separation) force for all the formulations evaluated are 
generally more homogeneous than the corresponding data for bioadhesion work (Figure 2B).  
This could indicate that once the samples have adhered to the mucosa, the detachment force is similar 
in all the formulations regardless of their composition, although a reverse behavior can be observed 
compared to the results for bioadhesion work. In general, greater force was required to separate each 
sample of chitosan-compacted formulations from vaginal mucosa: CQ > CK, CQH1 > CKH1 and 
CGQH1 > CGKH1. Moreover, the comparison between the detachment forces of compacted physical 
mixtures and compacted granule formulations (CQH1 vs. CGQH1, CQH2 vs. CGQH2, CKH1 vs. 
CGKH1, and CKH2 vs. CGKH2) clearly reveals a decrease in detachment forces for compacted 
granules with regard to the corresponding compacted physical mixtures; when PVP (binder agent) and 
ADCP (structural excipient) were included in the formulations, these excipients act as impurities that 
prevent the polymers from performing their mucoadhesive function. 




Figure 2. Vaginal bioadhesion work and maximum detachment force obtained for 
compacts and compacted granules (Mean Values + Standard Deviation, n = 6). 
2.3. Bioadhesion Residence Test 
Once it was verified that all the prepared formulations had mucoadhesive properties, the next step 
was to determine how long they remained bonded to the vaginal mucosa. Table 2 shows the periods of 
time this adhesion lasted when formulations were immersed in SVF and SVF/SSF. CQ and CK 
samples remained adhered to the vaginal mucosa for less than 30 min in the case of simulated vaginal 
fluid, while CH samples remained for 120 h. The mucoadhesive ability of HPMC has been extensively 
verified, and appears to derive from its stronger hydrogen bonding with the mucin compared to other 
natural polymers [35,36]. Therefore the combination of HPMC with marine polymers (chitosan or 
kappa-carrageenan) may produce a longer attachment according to data obtained from both natural 
polymers. As expected, CQH1, CQH2, CKH1, and CKH2 remained adhered to mucosa for a longer 
period of time (between 72 and 108 h) than CQ and CK samples. The longer bonding time of CKH1 
and CKH2 samples compared to CQH1 and CQH2 is due to kappa-carrageenan’s ability to form strong 
gels in the presence of potassium ions, which are part of the SVF composition. In other words, 
formulations that contain this polymer remain adhered to vaginal mucosa for longer than systems with 
chitosan. Chitosan is a polycationic copolymer consisting of glucosamine and N-acetylglucosamine 
units that are primarily responsible for swelling and the ensuing dissolution in contact with acidic 
fluid, and also have OH and NH2 groups that are considered essential for mucoadhesion [37]. 
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Table 2. Bioadhesion residence time of acyclovir compacts and compacted granule 
formulations in simulated vaginal fluid (SVF) and simulated vaginal fluid/simulated 
seminal fluid (SVF/SSF) mixture. 
Sample 
Bioadhesion Residence 
Time in SVF 
Bioadhesion Residence 
Time in SVF/SSF 
CQ <30 min --- 
CK <30 min --- 
CH 120 h --- 
CQH1 72 h --- 
CQH2 72 h --- 
CKH1 96 h --- 
CKH2 108 h --- 
CGQH1 72 h 72 h 
CGQH2 72 h 96 h 
CGKH1 72 h 72 h 
CGKH2 72 h 72 h 
The incorporation of a structural agent—anhydrous calcium hydrogen phosphate (ACP)—and  
a binder—polyvinyl pyrrolidone (PVP)—into the polymer blend to prepare wet granules produces 
compacted granules that remained adhered to the vaginal mucosa for the same period of time (72 h), 
regardless of the formulation composition or the pH of the medium (SFV or SVF/SSF mixture).  
This indicates that formulations obtained by combining HPMC with a natural polymer are reliable 
enough to remain adhered to the vaginal site for the time required to achieve ACV release, and 
consequently prevent the sexual transmission of genital herpes. If formulations were entirely composed 
of one polymer (chitosan, kappa-carrageenan or HPMC) they would have inappropriate mucoadhesion 
values, which may be deficient in the case of chitosan or kappa-carrageenan and excessive for HPMC. 
2.4. Swelling Behavior 
Swelling processes were visually detected during release studies and mucoadhesion tests; however, 
it is very important to quantify this process, as the swelling curves can help explain the release results. 
Swelling ratio (SR) values obtained from all formulations determined in SVF are shown in Figure 3. 
Each positive SR value indicates that at a given time the swollen matrix weight was higher than that of 
the dry system weight (t = 0). Conversely, each negative SR value shows that the weight of the swollen 
system was lower than the weight of the dry system (t = 0). The swelling data for CQ and CK 
formulations reveal that both polymers are erodible in acidic media, while CH has the highest swelling 
profile. When HPMC is combined with chitosan or carrageenan, the formulations showed intermediate 
swelling, which would be more acceptable in terms of patient comfort. An analysis of all the 
formulations made with polymer mixtures showed that their swelling behavior was conditioned by two 
factors: the nature of the natural polymer (chitosan or kappa-carrageenan), and the type of formulation 
(compact or compacted granules). Compact formulations with chitosan—CQH1 and CQH2—displayed 
lower swelling values than the kappa-carrageenan-based samples (CKH1 and CKH2). The explanation 
is that the presence of chitosan prevents HPMC’s own swelling pattern, as it produces a mixed 
HPMC/chitosan gel. CKH1 and CKH2 had very similar swelling profiles for the first 48 h of the test, 
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with a subsequent decrease in weight in inverse proportion to their HPMC content (CKH1 weight loss 
is greater than CKH2 weight loss), as kappa-carrageenan is unable to interact with HPMC. CKH1 and 
CKH2 swelling curves therefore have a similar shape to the CH swelling curve. The areas under the 
swelling curve are related to the amount of HPMC in each formulation. 
The swelling behavior of all compacted granule formulations is very similar, as they all showed 
swelling peaks between 350% and 510%, although the chitosan-based formulations CGQH1 and 
CGQH2 had a lower maximum swelling (350% and 452%, respectively). ACP plays a key role in the 
swelling process in these formulations. In formulations with kappa-carrageenan (CGKH1 and 
CGKH2), ACP creates a structure that prevents the free swelling of HPMC. In formulations with 
chitosan, the ACP structure prevents the formation of the HPMC-chitosan mixed gel. In other words, 
ACP acts by modulating the swelling of the polymers, resulting in systems with a similar swelling ratio 
which are very different from those obtained from formulations without this carrier. 
 
Figure 3. Swelling profiles obtained from compacts and compacted granules in simulated 
vaginal fluid. 
2.5. Cell Toxicity 
The biocompatibility of the different formulations was evaluated through in vitro cellular toxicity 
assays. The toxicity of the components was studied by incubation at room temperature for  
48 h at different concentrations before the assay to ensure that any potential toxic component of the 
materials would be present in the dilution. The cell culture was then treated with a suspension of the 
different dilutions. All the components were tested at a maximum concentration of 1000 μg/mL, except 
for chitosan, which was tested at 250 μg/mL due to solubility problems. 
Experiments were performed on a lymphoblastic cell line (MT-2) to evaluate toxicity on the 
immune cells present in vaginal or uterine mucosae and in the uterus epithelial cell line (HEC-1A) to 
assess potential damage to mucosae integrity. CC50 were calculated for the drug or empty material 
when possible. 
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As shown in Table 3 and Figure 4, no toxicity was detected at the concentrations tested except in 
the case of ACP, which showed mild toxicity in both cell lines, with a CC50 value of around  
1000 μg/mL. Acyclovir and all other materials showed no cytotoxicity at the maximum concentration 
tested, so CC50 values were not calculated. 
Table 3. CC50 values of acyclovir, chitosan, kappa-carrageenan, magnesium stearate, 
HPMC-K100M, ACP and PVP K30 in the cytotoxic assay in both MT-2 and HEC-1A cell 
lines. CC50: cytotoxic concentration 50%. 
Drug Cell Line CC50 
Acyclovir 
MT-2 >500 μM 
HEC-1A >500 μM 
Chitosan 
MT-2 >250 μg/mL 

















Figure 4. Graphic representation of the cytotoxic evaluation of acyclovir, chitosan,  
kappa-carrageenan, magnesium stearate, HPMC-K100M, ACP, and PVP K30. 
Cytotoxicity was measured in MT-2 cells and HEC-1A cells for 48 h. Cell viability is 
expressed as percentage of living cells compared to a non-treated control (100%). 
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3. Experimental Section 
3.1. Materials 
Acyclovir was obtained from Lab. Reig Jofré (Toledo, Spain). Chitosan with a deacetylation degree 
of 97% (CH, Lot: 8826900003) was supplied by Nessler (Madrid, Spain). Kappa-carrageenan (k; batch 
088K0178) was provided by Sigma-Aldrich (St. Louis, MO, USA). Hydroxyl-propyl-methyl-cellulose 
Methocel® K 100 M (HPMC; lot: DT352711) was a gift from Colorcon Ltd (Kent, UK).  
Anhydrous calcium hydrogen phosphate (ACP; batch: K93487944416) was provided by Merck 
(Darmstadt, Germany). Magnesium stearate PRS-CODEX (MGSt; batch: 85269 ALP) was purchased 
from Panreac (Barcelona, Spain). Kollidon® 30 (PVP K30; batch: 98-0820) was supplied by BASF 
(Ludwingshafen, Germany). All other reagents in this study were of analytical grade and used without 
further purification. Demineralized water was used in all cases. 
3.2. Preparation of Compacts and Compacted Granules 
Two types of solid formulations, compacts and compacted granules, were prepared containing 
natural and/or semisynthetic mucoadhesive polymers, and 100 mg of acyclovir. This selected drug 
amount is based in a common application of a marketed vaginal formulation (acyclovir topical cream 
5% w/w). The compacts (CQ, CK, CH, CQH1, CQH2, CKH1, and CKH2) were prepared from 
physical mixtures of the components, while the compacted granules (CGQH1, CGQH2, CGKH1, and 
CGKH2) were made from the corresponding granules in a pre-compacted stage. Granules were 
produced by adding a PVP K30 ethanol solution (binder agent) to a physical mixture of ACV, chitosan 
or kappa-carrageenan, HPMC, and ACP. ACP acts as structural agent. The wet mass was then passed 
through a 0.5 mm mesh and dried at 40 °C for 12 h. Magnesium stearate was added to the granules 
before compaction. Both types of systems were compacted according to the IR spectroscopy technique. 
A stainless steel disk was placed in a die assembly and the sample (physical mixture or granules) was 
added. A stainless steel disk was inserted in the cylinder bore on top of the sample. A piston was  
then placed inside the cavity, and the sample was pressed with a force of 5 t for 4 min. Finally, piston 
and disks were dismantled from the die and the acyclovir compact was removed and stored in  
a desiccator until use. 
3.3. Release Study 
All samples were placed in 100 mL DURAN laboratory borosilicate glass bottles containing 80 mL 
of release medium and stored in a shaking water bath (37 °C, 15 opm). Aliquots of 5 mL were 
withdrawn daily and filtered through Millipore® filters (0.45 μm). The medium was replaced with an 
equal volume of release medium equilibrated to temperature. Acyclovir concentrations were quantified 
by UV spectroscopy at a wavelength of 251 nm in a Shimadzu® UV-1700 spectrophotometer (Kyoto, 
Japan). The assay was made in triplicate in each case. In order to ensure that the formulations act as 
effective drug delivery carriers even in the presence of semen, the acyclovir release studies were 
carried out in two dissolution media: SVF (pH 4.2) and a SVF/SSF mixture (pH 7.6). In the first  
three hours of assay, the release medium was simulated vaginal fluid which was removed from each 
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bottle and substituted by the SVF/SSF 1:4 v/v mixture until the end of the assay. Both media were 
prepared according to the methodology described in the bibliography [38,39]. 
3.4. Characterization of Bioadhesion 
The bioadhesive capacity of the compacts and compacted granules was determined by measuring 
the maximum detachment force and the bioadhesion work using a TA-XT Plus texture analyzer (TA 
Instruments, Newcastle, UK), and bovine vaginal mucosa as substrate. Samples of bovine vaginal 
mucosa were obtained from a local slaughterhouse (Compostelana de Carnes S.L., Santiago de Compostela, 
Spain) immediately after slaughter. Each formulation was fixed to the upper support and the vaginal 
mucosa samples to the lower support using a cyanoacrylate adhesive. The mucosa was wetted with  
0.5 mL of warm simulated vaginal fluid, and the system was equilibrated and maintained at 37 °C for  
1 min. Finally a compression/extension stage was applied with an initial contact force of 0.5 N for  
60 s to ensure close contact between the substrate and the sample, followed by an extension phase at  
a rate of 1 mm/s until the total separation of the components. The results were recorded as force versus 
elongation. Bioadhesion work was calculated as the area under the force-elongation curve. All the 
formulations were evaluated six-fold. 
3.5. Bioadhesion Residence Test 
A complementary ex vivo mucoadhesion test was conducted based on the rotating cylinder 
technique [26,40] to evaluate the permanence of the bioadhesion of the mucoadhesive formulations to 
the vaginal mucosa. A sample of freshly excised vaginal bovine mucosa obtained from a local 
slaughterhouse was fixed with acrylic adhesive to a stainless steel prism with a width of 2 cm anda 
height of 3 cm. In order to provide a homogeneous force of adhesion between the vaginal mucosa and 
the solid formulation, each sample was placed over the vaginal mucosa and pressed with a weight of 
500 g for 30 s. The prism was then placed in a dissolution USP apparatus 1 (the basket was substituted 
by the prism) containing 500 mL of SVF at 37 ± 0.1 °C. The prism was fully immersed and agitated at 
30 rpm. The time elapsed until the complete detachment, dissolution and/or erosion of the dosage 
forms was visually assessed. To determine whether the presence of semen influences the time the 
formulation remains attached to the vaginal mucosa, the bioadhesion remanence test was conducted 
under the same conditions but changing the nature of the medium. The samples were maintained for 
three hours in SVF and the medium was then exchanged for the SVF/SSF 1:4 v/v mixture [26]. Two 
replicates of each bioadhesion residence test were carried out in all cases. 
3.6. Swelling Characterization 
The influence of composition on the behavior of compacts and compacted granules was studied by 
determining the degree of swelling in simulated vaginal fluid according to a method described by 
Ruiz-Caro and Veiga [41]. Before the samples were exposed to the SFV they were glued to metallic 
discs with a diameter of 30 mm. The discs were then placed in beakers containing 100 mL of SFV. 
These beakers were placed in a thermostated water shaking bath (Selecta® UNITRONIC320 OR, 
Barcelona, Spain) with an experimental temperature of 37 ± 0.1 °C and a shaking rate of 15 U/min.  
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At specific time intervals, the samples were extracted from the test medium and blotted with filter 
paper to absorb the excess liquid on the sample surface before the weight evaluation. The swelling 
ratio (SR) of each sample was calculated according to the following equation: SR = ((Ts − Td)/Td) × 100, 
where Ts and Td were the weights of the swollen and dried samples respectively [42]. All swelling 
tests were performed in triplicate. 
3.7. Cell and Cytotoxicity 
Two human cell lines were used: a lymphoblastic cell line, MT-2 [43] and a uterus/endometrium 
epithelial cell line, HEC-1-A [44] (kindly provided by María Angeles Muñoz, Hospital Gregorio 
Marañón, Madrid). Both cells were grown and propagated in RPMI 1640 medium supplemented with 
10% (v/v) foetal bovine serum, 2 mM L-glutamine and 50 μg/mL streptomycin at 37 °C with  
a humidified atmosphere of 5% CO2. The HEC-1-A cells were detached by removing the medium and 
rinsing the flask for 10 min with 1 to 2 mL of Trypsin 0.25%—EDTA 0.03% solution. The medium 
was replaced every third day after cell centrifugation at 1000 rpm for five minutes. 
Cell toxicity was measured by the widely-used MTT (3-(4, 5-dimethylthylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) method. Cells were incubated in 96-well plates at a density of 10 × 104 
cells per well in the case of MT-2, and 2 × 104 in the case of HEC-1-A in complete medium. To assess 
the cytotoxic effects of acyclovir and the excipients used in the different formulations, cells were 
exposed to fresh medium containing various concentrations of compounds, or with the same concentration 
of vehicle to dissolved compound (DMSO) for 48 h as controls in triplicate. The particles were 
suspended in water following a standard method [45]. After 48 h of incubation, 20 μL of MTT solution 
(7.5 mg/mL) was added to the plate and incubated for another two hours for MT-2 cells and  
three hours for HEC-1-A cells. The supernatant was then carefully removed and 100 μL of dimethyl 
sulfoxide (DMSO) was added to each well. Absorbance at a wavelength of 550 nm was measured in  
a Labtech LT-4000 microplate spectrophotometer. Values of cytotoxic concentrations 50 (CC50) were 
calculated using GraphPad Prism Software (non-linear regression, log inhibitor versus response).  
The results of the MTT assay represent the average of at least three individual experiments. 
4. Conclusions 
From the results presented above it can be concluded that the combination of a polymer of marine 
origin—chitosan or kappa-carrageenan—with a semisynthetic polymer—hydroxyl-propyl-methyl-
cellulose—in solid compacted formulations achieves the complete and sustained release of acyclovir 
over a period of between 220 and 260 h. These formulations can also adhere to the vaginal mucosa and 
remain adhered for 72 h. The swelling data of the formulations are influenced by the nature and 
quantity of the polymers they contain. Thus hydroxyl-propyl-methyl-cellulose has a higher degree of 
swelling than chitosan and kappa-carrageenan, which have lower swelling values and additionally are 
erodible in an acidic medium. The presence of anhydrous calcium hydrogen phosphate as a structural 
agent allows the modulation of the polymers’ swelling properties, reduces the swelling behavior of the 
hydroxyl-propyl-methyl-cellulose and prevents the formation of a mixed HPMC/chitosan gel.  
Of all the formulations developed, those containing chitosan are more indicated for preventing the 
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sexual transmission of genital herpes, as added to their beneficial characteristics of mucoadhesion and 
sustained release of ACV, they showed a preventive effect of chitosan against cell damage. 
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